2009 Clinical Trials Safety Terpenes 
The Cannigma
JANUARY 13, 2023
Based on the limited existing evidence, the best cannabis strain for migraines may be a Type II that includes both THC and CBD, and a terpene profile that includes beta-caryophyllene, myrcene, linalool, limonene, bisabolol, humulene or pinene. The study called out pinene, myrcene, and beta-caryophyllene as specifically useful terpenes.
The Cannigma
JULY 1, 2022
Because of this variability in the plant, and because of a lack of standard methods–like chemical analyses of cannabinoids or terpenes–has led to inconsistent scientific results. This is because these types of studies control the most variables to ensure that the results that come out of the trial are as reliable as possible.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
DECEMBER 12, 2022
It became illegal in the US in 2009. Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. As such, there have been numerous clinical trials using ketamine.
TheAnswerPage
JANUARY 11, 2022
For example, most, if not all, states have legalized the use of medical marijuana to treat specific health conditions for which there is no or only poor quality clinical evidence of efficacy and safety. Since 2009, Dr. Fisher-Corn has served as Editor-in-Chief of TheAnswerPage.com.
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Framings that more often carried a negative tone were related to poor evidence and safety issues.
Cannabis Law Report
OCTOBER 29, 2019
ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement. Wakshlag, DVM, Ph.D.,
Cannabis Law Report
JUNE 4, 2021
Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Originally a lawyer, Yang began working in startups and early stage growth companies as a founder or executive from 2000 to 2009.
Expert insights. Personalized for you.
132 
Let's personalize your content